| 1 |
33342939 | Differential Effects of DPP-4 Inhibitors, Anagliptin and Sitagliptin, on PCSK9 Levels in Patients with Type 2 Diabetes Mellitus who are Receiving Statin Therapy. | 2022 Jan 1 |
2 |
| 2 |
33751849 | Dipeptidyl peptidase-4 inhibitor, anagliptin, alters hepatic insulin clearance in relation to the glycemic status in Japanese individuals with type 2 diabetes. | 2021 Oct |
2 |
| 3 |
34268363 | Effects of anagliptin on the stress induced accelerated senescence of human umbilical vein endothelial cells. | 2021 May |
2 |
| 4 |
34737812 | Anagliptin alleviates lipopolysaccharide-induced inflammation, apoptosis and endothelial dysfunction of lung microvascular endothelial cells. | 2021 Dec |
1 |
| 5 |
34925661 | Anagliptin Monotherapy for Six Months in Patients With Type 2 Diabetes Mellitus and Hyper-Low-Density Lipoprotein Cholesterolemia Reduces Plasma Levels of Fasting Low-Density Lipoprotein Cholesterol and Lathosterol: A Single-Arm Intervention Trial. | 2021 Nov |
2 |
| 6 |
31990936 | Dipeptidyl peptidase-4 inhibitor anagliptin reduces fasting apolipoprotein B-48 levels in patients with type 2 diabetes: A randomized controlled trial. | 2020 |
4 |
| 7 |
32095176 | Comparison of Lipid-Lowering Effects of Anagliptin and Miglitol in Patients With Type 2 Diabetes: A Randomized Trial. | 2020 Feb |
1 |
| 8 |
32539832 | Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy. | 2020 Jun 15 |
3 |
| 9 |
33364803 | Effect of Anagliptin versus Sitagliptin on Inflammatory Markers: Sub-Analysis from the REASON Trial. | 2020 |
1 |
| 10 |
29766812 | Switching Dipeptidyl Peptidase-4 Inhibitors to Tofogliflozin, a Selective Inhibitor of Sodium-Glucose Cotransporter 2 Improve Arterial Stiffness Evaluated by Cardio-Ankle Vascular Index in Patients with Type 2 Diabetes: A Pilot Study. | 2019 |
2 |
| 11 |
30560227 | Postprandial Plasma Glucagon Kinetics in Type 2 Diabetes Mellitus: Comparison of Immunoassay and Mass Spectrometry. | 2019 Jan 1 |
1 |
| 12 |
30660990 | Anagliptin ameliorates high glucose- induced endothelial dysfunction via suppression of NLRP3 inflammasome activation mediated by SIRT1. | 2019 Mar |
2 |
| 13 |
31669625 | Effects of anagliptin on plasma glucagon levels and gastric emptying in patients with type 2 diabetes: An exploratory randomized controlled trial versus metformin. | 2019 Dec |
1 |
| 14 |
31733647 | Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: a secondary analysis of the REASON trial. | 2019 Nov 16 |
1 |
| 15 |
29715547 | Anagliptin inhibits neointimal hyperplasia after balloon injury via endothelial cell-specific modulation of SOD-1/RhoA/JNK signaling in the arterial wall. | 2018 Jun |
3 |
| 16 |
29977423 | Effect of Anagliptin on Glycemic and Lipid Profile in Patients With Type 2 Diabetes Mellitus. | 2018 Aug |
2 |
| 17 |
29980024 | LC/QTOF/MS/MS characterization, molecular docking and in silico toxicity prediction studies on degradation products of anagliptin. | 2018 Sep 10 |
2 |
| 18 |
30364744 | Efficacy of anagliptin as compared to linagliptin on metabolic parameters over 2 years of drug consumption: A retrospective cohort study. | 2018 Oct 15 |
1 |
| 19 |
28761658 | Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner. | 2017 |
1 |
| 20 |
27357182 | Anagliptin, A Dipeptidyl Peptidase-4 Inhibitor Ameliorates Arterial Stiffness in Association with Reduction of Remnant-Like Particle Cholesterol and Alanine Transaminase Levels in Type 2 Diabetic Patients. | 2016 |
1 |
| 21 |
25511640 | Additive effects of miglitol and anagliptin on insulin-treated type 2 diabetes mellitus: a case study. | 2015 Feb |
1 |
| 22 |
25819061 | A randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of anagliptin in drug-naïve patients with type 2 diabetes. | 2015 |
3 |
| 23 |
25834461 | Anagliptin in the treatment of type 2 diabetes: safety, efficacy, and patient acceptability. | 2015 |
1 |
| 24 |
26147347 | Anagliptin, a potent dipeptidyl peptidase IV inhibitor: its single-crystal structure and enzyme interactions. | 2015 Dec |
2 |
| 25 |
23075005 | Pharmacokinetics and metabolism of [14C]anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in humans. | 2013 May |
1 |
| 26 |
23749075 | [Preclinical and clinical aspects of the dipeptidyl peptidase-4 inhibitor anagliptin]. | 2013 Jun |
1 |
| 27 |
23972359 | The development of angioedema in a patient with type 2 diabetes due to a novel dipeptidyl peptidase-IV inhibitor, anagliptin. | 2013 Oct 3 |
1 |